Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts.

AIMS Monoamine oxidases (MAOs) are mitochondrial flavoenzymes responsible for neurotransmitter and biogenic amines catabolism. MAO-A contributes to heart failure progression via enhanced norepinephrine catabolism and oxidative stress. The potential pathogenetic role of the isoenzyme MAO-B in cardiac diseases is currently unknown. Moreover, it is has not been determined yet whether MAO activation can directly affect mitochondrial function. RESULTS In wild type mice, pressure overload induced by transverse aortic constriction (TAC) resulted in enhanced dopamine catabolism, left ventricular (LV) remodeling, and dysfunction. Conversely, mice lacking MAO-B (MAO-B(-/-)) subjected to TAC maintained concentric hypertrophy accompanied by extracellular signal regulated kinase (ERK)1/2 activation, and preserved LV function, both at early (3 weeks) and late stages (9 weeks). Enhanced MAO activation triggered oxidative stress, and dropped mitochondrial membrane potential in the presence of ATP synthase inhibitor oligomycin both in neonatal and adult cardiomyocytes. The MAO-B inhibitor pargyline completely offset this change, suggesting that MAO activation induces a latent mitochondrial dysfunction, causing these organelles to hydrolyze ATP. Moreover, MAO-dependent aldehyde formation due to inhibition of aldehyde dehydrogenase 2 activity also contributed to alter mitochondrial bioenergetics. INNOVATION Our study unravels a novel role for MAO-B in the pathogenesis of heart failure, showing that both MAO-driven reactive oxygen species production and impaired aldehyde metabolism affect mitochondrial function. CONCLUSION Under conditions of chronic hemodynamic stress, enhanced MAO-B activity is a major determinant of cardiac structural and functional disarrangement. Both increased oxidative stress and the accumulation of aldehyde intermediates are likely liable for these adverse morphological and mechanical changes by directly targeting mitochondria.

[1]  Céline Guilbeau-Frugier,et al.  p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. , 2013, Antioxidants & redox signaling.

[2]  Jun Ren,et al.  Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3β and mitochondrial function , 2012, BMC Medicine.

[3]  D. Kass,et al.  Pressure-volume relation analysis of mouse ventricular function. , 2011, American journal of physiology. Heart and circulatory physiology.

[4]  Roberta Menabò,et al.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. , 2011, Biochimica et biophysica acta.

[5]  D. Mochly‐Rosen,et al.  Mitochondrial aldehyde dehydrogenase and cardiac diseases , 2010, Cardiovascular research.

[6]  J. Molkentin,et al.  Extracellular signal‐regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy , 2010, Annals of the New York Academy of Sciences.

[7]  D. Kass,et al.  Monoamine Oxidase A–Mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload , 2010, Circulation research.

[8]  P. Pelicci,et al.  The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. , 2009, Biochimica et biophysica acta.

[9]  J. Doorn,et al.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. , 2009, Chemical research in toxicology.

[10]  M. Galinier,et al.  Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. , 2009, Journal of molecular and cellular cardiology.

[11]  J. Shih,et al.  Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.

[12]  M. Disatnik,et al.  Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart , 2008, Science.

[13]  C. Klaassen,et al.  Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  S. Meloche,et al.  Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo , 2007, Proceedings of the National Academy of Sciences.

[15]  G. Dorn,et al.  Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. , 2007, Physiology.

[16]  D. Kass,et al.  Role of oxidative stress in cardiac hypertrophy and remodeling. , 2007, Hypertension.

[17]  DimitriPchejetski,et al.  Oxidative Stress–Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A–Associated Cardiac Cell Apoptosis , 2007 .

[18]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[19]  E. Masini,et al.  Oxidative Stress by Monoamine Oxidase Mediates Receptor-Independent Cardiomyocyte Apoptosis by Serotonin and Postischemic Myocardial Injury , 2005, Circulation.

[20]  M. Lenhard,et al.  Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. , 2005, The Journal of clinical endocrinology and metabolism.

[21]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[22]  D. Pimentel,et al.  A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor‐independent ROS generation , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[24]  R. Pop-Busui,et al.  Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. , 2004, Journal of the American College of Cardiology.

[25]  R. Schwartz,et al.  Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. S. Zahm,et al.  Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. , 2004, Neurotoxicology.

[27]  C. Reggiani,et al.  Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency , 2003, Nature Genetics.

[28]  E. Billett,et al.  A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues , 2003, Cell and Tissue Research.

[29]  D. Kass,et al.  Protocols for hemodynamic assessment of transgenic mice in vivo. , 2003, Methods in molecular biology.

[30]  A. Yao,et al.  Sodium calcium exchanger plays a key role in alteration of cardiac function in response to pressure overload , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  G. Eisenhofer.  The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.

[32]  S. Gerber,et al.  The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. , 2001, Journal of molecular and cellular cardiology.

[33]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[34]  Y. Yamamura,et al.  Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. , 1998, Circulation.

[35]  Takeshi Kumazawa,et al.  Increased stress response and β–phenylethylamine in MAOB–deficient mice , 1997, Nature Genetics.

[36]  J. Shih,et al.  Increased stress response and beta-phenylethylamine in MAOB-deficient mice. , 1997, Nature genetics.

[37]  E. Cadenas,et al.  The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. , 1996, Archives of biochemistry and biophysics.

[38]  L. Gaboury,et al.  Apoptosis in pressure overload-induced heart hypertrophy in the rat. , 1996, The Journal of clinical investigation.

[39]  A. Quyyumi,et al.  Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.

[40]  J. Saffitz,et al.  Transmural heterogeneity of norepinephrine uptake in failing human hearts. , 1994, Journal of the American College of Cardiology.

[41]  M. Kashiki,et al.  Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. , 1993, Circulation.

[42]  S. Sakamoto,et al.  Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation. , 1989, The Journal of clinical investigation.

[43]  D. Murphy,et al.  Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. , 1986, Clinical chemistry.

[44]  R. Dorris.  A simple method for screening monoamine oxidase (MAO) inhibitory drugs for type preference. , 1982, Journal of Pharmacological Methods.